

Date: 25th March 2026
Ref: CORP 25/26 - 301

Dear xxx

Freedom of Information request: Treatment of Gastric Cancer (CORP 25/26 – 301)

Thank you for your request for information which the Trust received on 13th March 2026

Your Request:

1. *How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?*
2. *How many patients were treated in the past 3 months for gastric cancer (any stage) with:*
 - CAPOX (Capecitabine with Oxaliplatin)
 - FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
 - Lonsurf (Trifluridine - tipiracil)
 - Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
 - Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
 - Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
 - Zolbetuximab (Vyloy)
 - Any other systemic anti-cancer therapy
 - Palliative care only
3. *How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:*
 - CAPOX (Capecitabine with Oxaliplatin)
 - FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
 - Lonsurf (Trifluridine - tipiracil)
 - Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
 - Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
 - Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
 - Zolbetuximab (Vyloy)
 - Any other systemic anti-cancer therapy
 - Palliative care only

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



- **Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 0**
- **Zolbetuximab (Vyloy) - 0**
- **Any other systemic anti-cancer therapy - ***
- **Palliative care only - ***

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Question 4 is not applicable.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



